BUSINESS COMBINATION (Details Narrative) - USD ($) |
3 Months Ended | |||
|---|---|---|---|---|
Mar. 04, 2025 |
Mar. 31, 2026 |
Dec. 31, 2025 |
Jul. 29, 2025 |
|
| BUSINESS COMBINATION | ||||
| Retention description | amounts equal $400,000 of 50% of the Net Sales (as defined in the APA) of Lucemyra and 50% of the Net Distributable Profits (as defined in the APA) of the generic version of Lucemyra | |||
| Common stock shares issued | 500,000 | 500,000 | ||
| Closing market price | $ 0.31 | |||
| Common stock price per share | $ 0.31 | $ 0.001 | $ 0.001 | |
| Common stock purchase | 500,000 | |||
| Exercise price | $ 1.00 | $ 0.35 | ||
| Fair value of stock issued | $ 153,500 | |||
| Royalty payments | $ 108,260 | |||
| Upfront purchase price | $ 400,000 | $ 392,441 | ||
| Discounted at the risk-free rate | 4.04% | |||
| Discounted at required metric risk premium | 24.09% |
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Exercise price per share or per unit of warrants or rights outstanding. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Face amount or stated value per share of common stock. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The amount the entity has committed to make for future royalty guarantees. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of shares of stock issued attributable to transactions classified as other. No definition available.
|